Monte Rosa Therapeutics, Inc.
No enriched coverage for $GLUE in the last 7 days.
No SEC Form 4 filings for $GLUE in the last 30 days.
See all $GLUE insider activity →Monte Rosa Therapeutics (GLUE) shares dropped 4.8% after initiating a phase 2 study for MRT-2359 in mCRPC patients with AR mutations. The study will enroll up to 25 patients, with endpoints including PSA response and safety. The company previously reported positive phase 1/2 data for MRT-2359 combined with enzalutamide.
Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.
Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to
Recent GLUE coverage spans insider activity, financial news and market movers.
First‑in‑human dosing may trigger short‑term volatility and interest from biotech investors.
Cash runway into 2029 and multiple clinical readouts/initiations reduce near-term financing risk, but continued losses keep dilution risk in focus.
Near-term catalysts cluster in H2 2026 with GFORCE-1 readout and multiple MRT-8102 Phase 2 initiations, while balance-sheet runway extends to 2029.
Negative sentiment spillover from a comparable inflammation-reduction trial failure, with analyst PT cut and “setback” framing.
The article frames a sharp risk-off repricing for Monte Rosa due to clinical failure read-across from IL-6 to IL-1/IL-18 inflammation programs.
alphai scores every news story that mentions GLUE with an AI model for sentiment and relevance, and aggregates insider trades from Monte Rosa Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Monte Rosa Therapeutics (GLUE) shares dropped 4.8% after initiating a phase 2 study for MRT-2359 in mCRPC patients with AR mutations. The study will enroll up to 25 patients, with endpoints including PSA response and safety. The company previously reported positive phase 1/2 data for MRT-2359 combined with enzalutamide.
1 min readMonte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.
1 min readMonte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to
6 min readBioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) fell after Novo Nordisk (NVO) reported its late-stage ZEUS trial for ziltivekimab failed to reduce heart attack, stroke, and related deaths despite lowering inflammation markers. BIOA dropped 64% and GLUE about 27%. Analysts cut BIOA and GLUE price targets while keeping Buy ratings.
4 min readAmazon shares rally as cloud growth surges and spending outlook climbs Investing.com -- Monte Rosa Therapeutics shares plummeted nearly 29.9% in pre-open trading today, trading at $15.90, after Novo Nordisk disclosed that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab — an IL-6 pathway inhibitor — failed to demonstrate a statistically meaningful reduction in major adverse cardiovascular events versus placebo in patients with atherosclerotic cardiovascular disease, chronic...
4 min readWarmuth Markus (President & CEO) sold 9,500 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.18 ($0.22M total) on 2026-07-16.
1 min readMonte Rosa Therapeutics (Nasdaq: GLUE) said it granted inducement equity awards to three newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). Awards include non-qualified stock options for 18,025 shares (exercise price $24.02) and restricted stock units for 3,900 shares, both subject to service-based vesting.
2 min readManning Anthony M. sold 10,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.11 ($0.23M total) on 2026-06-29.
2 min readJanku Filip (Chief Medical Officer) sold 41,845 shares of Monte Rosa Therapeutics, Inc. (GLUE) at an average of $21.08 ($20.22–$21.42, $0.88M total) across 2 trades over 2026-06-23 to 2026-06-24 under a Rule 10b5-1 trading plan.
2 min readMonte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001826457 false 0001826457 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
2 min read
